Screening for Early Endocrine Reserve Changes During Major Physiological Transitions

Abstract

Major physiological transitions, including puberty, pregnancy, perimenopause, and aging, are characterized by dynamic alterations in endocrine function that may unmask or accelerate underlying endocrine reserve limitations. Early identification of subclinical endocrine insufficiency during these transitions is critical for optimizing patient outcomes, yet remains underutilized in routine clinical practice. This review synthesizes current evidence regarding screening strategies, pathophysiology, epidemiology, risk factors, diagnostic modalities, and management approaches for early endocrine reserve changes during key physiological milestones. Emphasis is placed on practical implications for clinical care, recent advances in biomarkers and imaging, and recommendations from leading endocrine societies.

Introduction

Endocrine reserve denotes the capacity of an endocrine gland to maintain adequate hormonal output in response to physiological stress or increased demand. During major physiological transitions—such as puberty, pregnancy, perimenopause, and advanced aging—there is often a heightened requirement for hormonal adaptation. For individuals with marginal endocrine reserve, these transitions can precipitate overt dysfunction or disease. Timely screening and intervention may prevent long-term complications, yet consensus on optimal strategies remains elusive. This review aims to provide an evidence-based overview of the importance and methodology of screening for early endocrine reserve changes during significant physiological transitions, with a focus on clinical relevance and emerging best practices.

Epidemiology / Disease Burden

Disorders of endocrine reserve, including subclinical hypothyroidism, adrenal insufficiency, and primary ovarian insufficiency, have a variable prevalence depending on the population and transition context. For example, subclinical thyroid dysfunction affects up to 10% of women during pregnancy, while decline in ovarian reserve is nearly universal during the perimenopausal years. The burden of undiagnosed or delayed recognition can be substantial, resulting in adverse pregnancy outcomes, impaired pubertal progression, and increased morbidity in aging adults. The epidemiology is further complicated by the often asymptomatic nature of early reserve depletion, which underscores the need for targeted screening in at-risk groups.

Pathophysiology

Endocrine reserve is determined by the structural and functional integrity of hormone-producing cells, the regulatory feedback mechanisms, and the capacity for compensatory upregulation. During periods of physiological transition, increased hormonal demands can exceed the residual functional capacity of compromised glands. For instance, the pituitary-adrenal axis may fail to mount an adequate response during acute stress in the elderly, while diminished ovarian follicle pool during perimenopause leads to erratic estrogen production and altered gonadotropin feedback. Understanding these mechanisms is critical for interpreting early biochemical changes and for distinguishing adaptive from pathologic endocrine alterations.

Risk Factors

Multiple factors can predispose individuals to early depletion of endocrine reserve. Genetic predisposition, autoimmune processes, prior glandular insults (e.g., surgery, irradiation), chronic illnesses, and environmental exposures all contribute. For example, family history and autoimmune markers are well-established risk factors for premature ovarian insufficiency and autoimmune thyroiditis. In the context of pregnancy, pre-existing thyroid autoimmunity and obesity increase the risk of thyroid reserve depletion. Identifying modifiable and non-modifiable risk factors is essential for targeted screening and prevention strategies.

Clinical Features

The initial phases of declining endocrine reserve are frequently asymptomatic or manifest with nonspecific symptoms that overlap with normal physiological changes. Early features may include subtle fatigue, mood changes, menstrual irregularities, or mild electrolyte disturbances. In adolescents, impaired pubertal progression or growth delay may be the first sign of pituitary or gonadal insufficiency. During pregnancy, unrecognized thyroid dysfunction may present only with mild fatigue or weight changes, yet have significant implications for fetal development. Clinical vigilance and high index of suspicion are warranted, especially in high-risk populations.

Diagnosis

Screening for early endocrine reserve changes relies on a combination of clinical assessment and laboratory evaluation. Basal hormone levels (e.g., TSH, FSH, AMH, cortisol), dynamic stimulation or suppression tests, and emerging biomarkers (e.g., inhibin B, proinsulin:C-peptide ratio) offer insights into endocrine reserve status. Imaging modalities, such as ovarian ultrasound for antral follicle count or pituitary MRI, may be indicated in select cases. Interpretation of results must account for physiological adaptations associated with the specific transition, as normative reference ranges may differ. Serial monitoring can help distinguish transient from persistent abnormalities.

Treatment & Management

Management of early endocrine reserve changes is tailored to the underlying cause, severity, and clinical context. In many cases, monitoring and patient education may suffice, particularly when biochemical changes are mild and asymptomatic. Hormone replacement therapy is indicated for overt insufficiency or in high-risk settings (e.g., hypothyroidism in pregnancy, adrenal insufficiency with stress). Lifestyle modification, optimization of comorbidities, and addressing modifiable risk factors are adjunctive strategies. Interdisciplinary care, including endocrinology, primary care, and reproductive medicine, enhances outcomes for complex cases.

Recent Advances / Emerging Therapies

Recent years have seen significant advances in the detection and management of early endocrine reserve changes. Highly sensitive assays for hormonal biomarkers, such as ultrasensitive TSH and AMH, have improved the ability to detect subclinical dysfunction. Molecular and genetic testing are increasingly used for risk stratification, especially in familial syndromes. Novel therapies, such as ovarian tissue preservation and regenerative approaches, are under investigation for at-risk populations. Digital health tools and artificial intelligence algorithms are being explored for risk prediction and decision support.

Guideline Recommendations

Multiple professional societies, including the Endocrine Society, American Thyroid Association, and European Society of Endocrinology, have released guidelines on screening for endocrine dysfunction during physiological transitions. Key recommendations include targeted screening for thyroid dysfunction in pregnancy, early menopause in women with risk factors, and adrenal insufficiency in older adults with unexplained fatigue or hypotension. Guidelines emphasize individualized risk assessment, use of appropriate reference ranges, and the importance of shared decision-making with patients regarding management options.

Conclusion

Proactive screening for early endocrine reserve changes during major physiological transitions represents a critical but often overlooked opportunity to prevent morbidity and optimize lifelong health. Advances in diagnostics and risk stratification are enhancing clinicians ability to identify at-risk individuals and intervene early. Integration of guideline-based screening into routine clinical practice, coupled with ongoing research and education, will be key to improving outcomes across diverse populations.